Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis

Clinical Infectious Diseases

Volumn 34, Issue 12, 2002, Pages 1607-1612

  Dooley, Kelly E ^a   Golub, Jonathan ^a,c   Goes, Fernando S ^a   Merz, William G ^a   Sterling, Timothy R ^a,b,d  

^a Department of Medicine ^*  (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MARYLAND DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^d Baltimore City Health Department Eastern Chest Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ETHAMBUTOL; GATIFLOXACIN; GENOMIC DNA; ISONIAZID; LEVOFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TROVAFLOXACIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DYSPNEA; FEMALE; FEVER; HUMAN; LUNG LAVAGE; MALE; MYCOBACTERIUM TUBERCULOSIS; PLEURISY; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; TUBERCULOSIS;

ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; TUBERCULOSIS;

EID: 0037097530     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/340618     Document Type: Article

References (21)

1. Practice guidelines for the management of community-acquired pneumonia
2. Guidelines for the management of adults with community-acquired pneumonia
3. The use of quinolones in developing countries
4. Comparative in vitro activity of five fluoroquinolones against mycobacteria
5. In vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis
6. In vitro activity of quinolones and macrolides against mycobacteria
7. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis
8. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis
9. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis
10. Patient and health care system delays in the diagnosis and treatment of tuberculosis
11. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: Recommendations for a standardized methodology
12. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country
13. Inappropriate use of antibiotics and the risk for delayed admission and masked diagnosis of infectious diseases
14. Can administration of a fluoroquinolone delay diagnosis of pulmonary tuberculosis?
15. Delayed diagnosis of pulmonary tuberculosis in city hospitals
16. Delays in the suspicion and treatment of tuberculosis among hospitalized patients
17. Progress toward the elimination of tuberculosis - United States, 1998
18. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis
19. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis
20. Emergence of fluoroquinolone-resistant tuberculosis in New York City